Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy, safety and tolerability of Ivermectin in patients
with mild SARS-CoV-2 infection, in the rate of progression to severe 2019 novel coronavirus
disease (COVID-19).
The primary efficacy endpoint is the proportion of participants with a disease control status
defined as no progression of severe disease Hypothesis (H0): There is no difference between
group A (ivermectin + paracetamol) and group B (ivermectin + paracetamol) in terms of the
primary endpoint on day 14.
Phase:
Phase 2
Details
Lead Sponsor:
Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.